Home Cart Sign in  
Chemical Structure| 68-41-7 Chemical Structure| 68-41-7

Structure of D-Cycloserine
CAS No.: 68-41-7

Chemical Structure| 68-41-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

D-Cycloserine is a broad-spectrum antibiotic against Gram-negative bacteria working by inhibiting cell wall biosynthesis (D-Ala peptide bond formation). It is also a partial agonist at the glycine modulatory site of NMDA glutamatergic receptors.

Synonyms: α-Cycloserine; RO-1-9213; Oxamycin

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of D-Cycloserine

CAS No. :68-41-7
Formula : C3H6N2O2
M.W : 102.09
SMILES Code : O=C1NOC[C@H]1N
Synonyms :
α-Cycloserine; RO-1-9213; Oxamycin
MDL No. :MFCD00005353
InChI Key :DYDCUQKUCUHJBH-UWTATZPHSA-N
Pubchem ID :6234

Safety of D-Cycloserine

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
CA1 pyramidal neurons in hippocampal brain slices 20 µM To investigate the modulation of hippocampal synaptic plasticity by DCS, it was found that DCS enhances NMDAR-dependent long-term potentiation (LTP) and long-term depression (LTD) Transl Psychiatry. 2024 Jan 9;14(1):18
Mycobacterium tuberculosis H37Rv 64 µg/mL 4 weeks Determine the spontaneous mutation rate of D-cycloserine Nat Commun. 2019 Sep 13;10(1):4177
Mycobacterium tuberculosis H37Rv 100 µg/mL 4 weeks Determine the spontaneous mutation rate of D-cycloserine Nat Commun. 2019 Sep 13;10(1):4177
E. coli DdlB (EcDdlB) 5 mM DCS Investigate the mechanism of D-cycloserine inhibition of D-alanine:D-alanine ligase, revealing that D-cycloserine inhibits the enzyme via a phosphorylated form (DCSP). Nat Commun. 2017 Dec 5;8(1):1939

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Sprague-Dawley rats Morphine-dependent rat model Intraperitoneal injection 15 mg/kg Single dose, administered immediately prior to extinction training D-cycloserine facilitates extinction of morphine withdrawal-associated place aversion Biol Psychiatry. 2010 Jan 1;67(1):85-7
Children Autism Spectrum Disorder Oral 50 mg Once weekly for 10 weeks To assess the efficacy and adverse effects of D-cycloserine plus social skills training compared to placebo plus social skills training on social and communication skills in children with ASD. Results showed little to no difference between D-cycloserine and placebo in social interaction, communication, and stereotyped patterns of behavior at one week and 12 weeks post-treatment. Cochrane Database Syst Rev. 2021 Feb 14;2(2):CD013457
Rats Alcohol drinking model Intraperitoneal injection 10 mg/kg Single dose, 15–20 min before To study the effect of DCS on aversion-resistant alcohol intake, results showed DCS significantly reduced aversion-resistant alcohol intake but had no effect on quinine-free alcohol intake Neuropsychopharmacology. 2015 Sep;40(10):2357-67
Sprague-Dawley rats Spared nerve injury (SNI) and cisplatin-induced neuropathy Oral 3, 10, or 30 mg/kg Twice daily for 14 days DCS treatment resulted in a dose-dependent reduction in mechanical sensitivity of the injured limb, with effects persisting for weeks after cessation of treatment. Re-exposure to DCS further enhanced antinociceptive behavior. Repeated oral DCS also reduced cancer chemotherapy drug-induced neuropathic pain behavior. Pain. 2007 Nov;132(1-2):108-23

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00257361 Obsessive Compulsive Disorder PHASE2 WITHDRAWN - -
NCT00000194 Opioid-Related Disorders PHASE2 WITHDRAWN 1998-01-01 VA Connecticut Healthcare Syst... More >>em, New Haven, Connecticut, 06519, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

9.80mL

1.96mL

0.98mL

48.98mL

9.80mL

4.90mL

97.95mL

19.59mL

9.80mL

References

 

Historical Records

Categories